Intensity Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.34 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.90M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.